Home

SMN

Scottish Mesothelioma Network

The Scottish Mesothelioma Network, working in partnership with Macmillan Cancer Support, Mesothelioma UK and NHS Scotland, is comprised of a team of clinicians from across Scotland who collaborate to share best practice and provide high-quality clinical care, information and support to all patients, wherever they live in the country. The network ensures all patients have equitable access to potentially life-changing clinical trials.

What is Mesothelioma?

Mesothelioma is a rare cancer that most commonly occurs in the lining of the lung (pleura).  It can also occur in the lining of the abdomen  (peritoneum) and the lining of the heart (pericardium). The main symptoms are shortness of breath, chest pain, cough and tiredness.  Being exposed to asbestos is a major contributing factor.

MITOPE Trial

This clinical trial offers a new treatment option for MPE and mesothelioma patients using RS Oncology’s novel drug known as RSO-021. This new drug targets a specific mitochondrial enzyme (PRX3) by regulating oxidative stress to eliminate cancer cells while sparing normal cells. RSO-021 is administered weekly locally into the pleural cavity using an intrapleural catheter immediately after the pleural effusion is drained.

This clinical trial is available to patients who are at least 18 years old suffering from MPE and/or mesothelioma, and have documented tumor progression after receiving at least one prior standard of care treatment.  The trial will also soon be widening to include patients who had not had any treatment as a first line option.

For more information please contact carolyn.macrae@ggc.scot.nhs.uk

The MITOPE trial is now opened in the Queen Elizabeth University Hospital.

macmillan cancer support logo
macmillan cancer support logo

Recent News

ERS International congress – 7-11 September 2024, Vienna

Pleural Research day – 4-5 July 2024, Oxford

Summer BTS  – 20-21 June 2024, Manchester

Carers Course